Share Price and Basic Stock Data
Last Updated: December 10, 2025, 10:32 pm
| PEG Ratio | -1.56 |
|---|
Analyst Insight & Comprehensive Analysis
AI Stock Ranker – Real-Time Fundamental Strength Score
Business Overview and Revenue Trends
Wanbury Ltd operates within the pharmaceuticals sector, a domain that is both vital and competitive. As of its latest reporting, the company’s share price stood at ₹239, with a market capitalization of ₹833 Cr. Over the past few quarters, Wanbury has demonstrated a commendable upward trajectory in sales, with figures rising from ₹117 Cr in June 2022 to ₹146 Cr in June 2023, and maintaining a slight dip to ₹144 Cr in September 2023. However, the trend seems to be recovering, with sales expected to rebound to ₹161 Cr by September 2024. This indicates a possible resilience amid market fluctuations. The trailing twelve months (TTM) revenue is reported at ₹630 Cr, reflecting a steady growth trajectory that could catch the attention of investors looking for stability in the pharmaceutical sector.
Profitability and Efficiency Metrics
Profitability has been a mixed bag for Wanbury, with the operating profit margin (OPM) fluctuating significantly. The OPM stood at a modest 15% recently, but it has seen a remarkable recovery from negative levels recorded in mid-2022. The net profit for the latest reporting period was ₹43 Cr, showcasing a positive shift from the previous year’s losses. The company’s return on equity (ROE) is strikingly high at 76.5%, signaling efficient management of shareholder funds. However, the interest coverage ratio (ICR) is a concern at 2.16x, suggesting that while the company can meet its interest obligations, there is limited room for error. Wanbury’s cash conversion cycle (CCC) of -55 days indicates that it is able to turn inventory and receivables into cash swiftly, which is a strong point for operational efficiency.
Balance Sheet Strength and Financial Ratios
Analyzing Wanbury’s balance sheet reveals a blend of strengths and vulnerabilities. The company reported total borrowings of ₹179 Cr against reserves of just ₹26 Cr, which raises questions about its long-term financial health. The debt-to-equity ratio stands at 2.92x, indicating that the company is highly leveraged. However, the reported book value per share has rebounded to ₹18.09, a significant turnaround from the negative figures observed in prior years. This improvement in book value suggests that Wanbury is on a path to restoring shareholder value. The current ratio of 1.11x provides a level of comfort regarding short-term liquidity, although it remains close to the threshold that signals potential liquidity issues, especially in a capital-intensive industry like pharmaceuticals.
Shareholding Pattern and Investor Confidence
Wanbury’s shareholding structure reflects a predominant public interest, with 59.55% of shares held by the public as of the latest reporting. The promoter holding stands at 39.63%, which has seen a slight decline over recent months, potentially indicating a shift in confidence or strategy among the promoters. Foreign institutional investors (FIIs) have gradually increased their stake from negligible levels to 0.80%, suggesting a cautious but growing interest from external investors. The number of shareholders has also seen an upward trend, rising to 17,774, which may reflect growing investor confidence. However, the low institutional ownership can be seen as a double-edged sword; while it may suggest room for expansion, it may also indicate a lack of confidence from larger investors in the company’s long-term prospects.
Outlook, Risks, and Final Insight
Looking ahead, Wanbury Ltd presents both opportunities and challenges for potential investors. The impressive ROE and efficient cash conversion cycle are strong points, suggesting that the company is well-managed and capable of generating returns. However, the high leverage and fluctuating profitability metrics pose significant risks. Investors should be cautious about the implications of continued high debt levels, particularly in an industry that can be susceptible to regulatory changes and market competition. Moreover, while the recent sales growth is encouraging, the company must sustain this momentum to reassure investors. Overall, Wanbury appears to be at a crossroads; it could either solidify its position as a competitive player in the pharmaceutical sector or face hurdles that could impact its recovery strategy. Investors will need to weigh these factors carefully when considering their next move.
Source: Getaka Fundamental Analysis | Generated using proprietary financial data.
Competitors of Wanbury Ltd
| Stock Name ⇩ | Market Cap ⇩ | Current Price ⇩ | High / Low ⇩ | Stock P/E ⇩ | Book Value ⇩ | Dividend Yield ⇩ | ROCE ⇩ | ROE ⇩ | Face Value ⇩ |
|---|---|---|---|---|---|---|---|---|---|
| Lactose (India) Ltd | 142 Cr. | 113 | 244/84.3 | 31.4 | 49.6 | 0.00 % | 12.9 % | 9.69 % | 10.0 |
| MPS Pharmaa Ltd | 3.36 Cr. | 1.76 | 4.33/1.76 | 0.33 | 0.00 % | 9.79 % | 59.0 % | 10.0 | |
| Gujarat Themis Biosyn Ltd | 4,169 Cr. | 383 | 479/192 | 86.3 | 24.3 | 0.17 % | 27.3 % | 21.7 % | 1.00 |
| Gujarat Terce Laboratories Ltd | 32.4 Cr. | 43.6 | 92.2/37.2 | 10.6 | 0.00 % | 41.4 % | 14.6 % | 10.0 | |
| Gujarat Inject (Kerala) Ltd | 45.3 Cr. | 30.9 | 31.0/17.0 | 108 | 6.93 | 0.00 % | 13.5 % | 11.0 % | 10.0 |
| Industry Average | 20,300.20 Cr | 1,152.20 | 52.34 | 202.18 | 0.36% | 16.29% | 15.20% | 6.10 |
Quarterly Result
| Metric | Jun 2022 | Sep 2022 | Dec 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 117 | 124 | 126 | 133 | 146 | 144 | 146 | 139 | 131 | 161 | 133 | 172 | 163 |
| Expenses | 120 | 118 | 119 | 119 | 133 | 127 | 124 | 121 | 120 | 141 | 120 | 142 | 139 |
| Operating Profit | -3 | 6 | 6 | 14 | 13 | 17 | 21 | 18 | 11 | 20 | 14 | 30 | 24 |
| OPM % | -3% | 5% | 5% | 11% | 9% | 12% | 15% | 13% | 8% | 12% | 10% | 17% | 15% |
| Other Income | 2 | 1 | 0 | -3 | 1 | 1 | 1 | 26 | 1 | 2 | 1 | 2 | 0 |
| Interest | 3 | 4 | 7 | 8 | 6 | 8 | 8 | 7 | 8 | 10 | 10 | 9 | 8 |
| Depreciation | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 3 | 4 |
| Profit before tax | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 19 | 14 |
| Tax % | -3% | 25% | 8% | -11% | 6% | -2% | -0% | 1% | 0% | 2% | 5% | -6% | 1% |
| Net Profit | -7 | -1 | -3 | 1 | 5 | 7 | 10 | 34 | 1 | 8 | 1 | 20 | 13 |
| EPS in Rs | -2.21 | -0.27 | -1.00 | 0.31 | 1.43 | 2.25 | 3.14 | 10.27 | 0.32 | 2.45 | 0.37 | 6.18 | 4.10 |
Last Updated: August 20, 2025, 1:15 am
Below is a detailed analysis of the quarterly data for Wanbury Ltd based on the most recent figures (Jun 2025) and their trends compared to the previous period:
- For Sales, as of Jun 2025, the value is 163.00 Cr.. The value appears to be declining and may need further review. It has decreased from 172.00 Cr. (Mar 2025) to 163.00 Cr., marking a decrease of 9.00 Cr..
- For Expenses, as of Jun 2025, the value is 139.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 142.00 Cr. (Mar 2025) to 139.00 Cr., marking a decrease of 3.00 Cr..
- For Operating Profit, as of Jun 2025, the value is 24.00 Cr.. The value appears to be declining and may need further review. It has decreased from 30.00 Cr. (Mar 2025) to 24.00 Cr., marking a decrease of 6.00 Cr..
- For OPM %, as of Jun 2025, the value is 15.00%. The value appears to be declining and may need further review. It has decreased from 17.00% (Mar 2025) to 15.00%, marking a decrease of 2.00%.
- For Other Income, as of Jun 2025, the value is 0.00 Cr.. The value appears to be declining and may need further review. It has decreased from 2.00 Cr. (Mar 2025) to 0.00 Cr., marking a decrease of 2.00 Cr..
- For Interest, as of Jun 2025, the value is 8.00 Cr.. The value appears to be improving (decreasing) as expected. It has decreased from 9.00 Cr. (Mar 2025) to 8.00 Cr., marking a decrease of 1.00 Cr..
- For Depreciation, as of Jun 2025, the value is 4.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 3.00 Cr. (Mar 2025) to 4.00 Cr., marking an increase of 1.00 Cr..
- For Profit before tax, as of Jun 2025, the value is 14.00 Cr.. The value appears to be declining and may need further review. It has decreased from 19.00 Cr. (Mar 2025) to 14.00 Cr., marking a decrease of 5.00 Cr..
- For Tax %, as of Jun 2025, the value is 1.00%. The value appears to be increasing, which may not be favorable. It has increased from -6.00% (Mar 2025) to 1.00%, marking an increase of 7.00%.
- For Net Profit, as of Jun 2025, the value is 13.00 Cr.. The value appears to be declining and may need further review. It has decreased from 20.00 Cr. (Mar 2025) to 13.00 Cr., marking a decrease of 7.00 Cr..
- For EPS in Rs, as of Jun 2025, the value is 4.10. The value appears to be declining and may need further review. It has decreased from 6.18 (Mar 2025) to 4.10, marking a decrease of 2.08.
Overall, while many items appear to show a positive trend, any significant downward movement warrant further investigation.
Profit & Loss - Annual Report
Last Updated: October 15, 2025, 4:08 am
| Metric | Sep 2014n n 18m | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | TTM |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 661 | 250 | 420 | 432 | 370 | 391 | 367 | 392 | 511 | 485 | 578 | 600 | 630 |
| Expenses | 637 | 228 | 387 | 414 | 438 | 375 | 344 | 374 | 475 | 459 | 503 | 520 | 542 |
| Operating Profit | 25 | 21 | 33 | 19 | -68 | 16 | 23 | 18 | 36 | 26 | 75 | 80 | 88 |
| OPM % | 4% | 9% | 8% | 4% | -18% | 4% | 6% | 5% | 7% | 5% | 13% | 13% | 14% |
| Other Income | -78 | 6 | 0 | 90 | 76 | 9 | 84 | 2 | 77 | -3 | 24 | -0 | 5 |
| Interest | 48 | 19 | 32 | 36 | 31 | 40 | 33 | 23 | 21 | 21 | 29 | 37 | 37 |
| Depreciation | 23 | 5 | 9 | 10 | 10 | 10 | 10 | 10 | 11 | 12 | 13 | 13 | 14 |
| Profit before tax | -125 | 4 | -7 | 62 | -32 | -25 | 65 | -12 | 81 | -10 | 56 | 30 | 42 |
| Tax % | 2% | 28% | 0% | 1% | -1% | -1% | 0% | 2% | -0% | 1% | 1% | -3% | |
| Net Profit | -128 | 3 | -7 | 62 | -32 | -25 | 64 | -13 | 81 | -10 | 56 | 31 | 43 |
| EPS in Rs | -63.95 | 1.60 | -3.58 | 26.71 | -13.49 | -10.48 | 25.79 | -5.04 | 24.94 | -3.18 | 17.09 | 9.32 | 13.10 |
| Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
YoY Net Profit Growth
| Year | 2016-2017 | 2017-2018 | 2018-2019 | 2019-2020 | 2020-2021 | 2021-2022 | 2022-2023 | 2023-2024 | 2024-2025 |
|---|---|---|---|---|---|---|---|---|---|
| YoY Net Profit Growth (%) | 985.71% | -151.61% | 21.88% | 356.00% | -120.31% | 723.08% | -112.35% | 660.00% | -44.64% |
| Change in YoY Net Profit Growth (%) | 0.00% | -1137.33% | 173.49% | 334.12% | -476.31% | 843.39% | -835.42% | 772.35% | -704.64% |
Wanbury Ltd has shown an inconsistent trend in YoY Net Profit Growth (%) in the last 9 years from 2016-2017 to 2024-2025.
Growth
| Compounded Sales Growth | |
|---|---|
| 10 Years: | 9% |
| 5 Years: | 10% |
| 3 Years: | 5% |
| TTM: | 12% |
| Compounded Profit Growth | |
|---|---|
| 10 Years: | 25% |
| 5 Years: | 30% |
| 3 Years: | 75% |
| TTM: | 60% |
| Stock Price CAGR | |
|---|---|
| 10 Years: | 16% |
| 5 Years: | 49% |
| 3 Years: | 61% |
| 1 Year: | 15% |
| Return on Equity | |
|---|---|
| 10 Years: | % |
| 5 Years: | % |
| 3 Years: | % |
| Last Year: | 70% |
Last Updated: September 5, 2025, 1:55 pm
Balance Sheet
Last Updated: October 10, 2025, 3:15 pm
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Equity Capital | 20 | 20 | 20 | 23 | 24 | 24 | 25 | 25 | 33 | 33 | 33 | 33 |
| Reserves | -212 | -214 | -209 | -176 | -208 | -233 | -168 | -181 | -56 | -66 | -5 | 26 |
| Borrowings | 389 | 381 | 362 | 300 | 250 | 260 | 190 | 192 | 100 | 95 | 116 | 179 |
| Other Liabilities | 209 | 209 | 215 | 265 | 207 | 236 | 232 | 253 | 276 | 241 | 199 | 176 |
| Total Liabilities | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
| Fixed Assets | 174 | 164 | 180 | 186 | 178 | 172 | 164 | 167 | 167 | 167 | 167 | 201 |
| CWIP | 13 | 19 | 14 | 10 | 10 | 9 | 14 | 11 | 2 | 2 | 3 | 5 |
| Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other Assets | 219 | 213 | 193 | 216 | 84 | 105 | 101 | 111 | 183 | 135 | 173 | 208 |
| Total Assets | 406 | 396 | 388 | 412 | 273 | 286 | 279 | 289 | 353 | 304 | 343 | 414 |
Below is a detailed analysis of the balance sheet data for Wanbury Ltd based on the most recent figures (Mar 2025) and their trends compared to the previous period:
- For Equity Capital, as of Mar 2025, the value is 33.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 33.00 Cr..
- For Reserves, as of Mar 2025, the value is 26.00 Cr.. The value appears strong and on an upward trend. It has increased from -5.00 Cr. (Mar 2024) to 26.00 Cr., marking an increase of 31.00 Cr..
- For Borrowings, as of Mar 2025, the value is 179.00 Cr.. The value appears to be increasing, which may not be favorable. However, Borrowings exceed Reserves, which may signal higher financial risk. It has increased from 116.00 Cr. (Mar 2024) to 179.00 Cr., marking an increase of 63.00 Cr..
- For Other Liabilities, as of Mar 2025, the value is 176.00 Cr.. The value appears to be improving (decreasing). It has decreased from 199.00 Cr. (Mar 2024) to 176.00 Cr., marking a decrease of 23.00 Cr..
- For Total Liabilities, as of Mar 2025, the value is 414.00 Cr.. The value appears to be increasing, which may not be favorable. It has increased from 343.00 Cr. (Mar 2024) to 414.00 Cr., marking an increase of 71.00 Cr..
- For Fixed Assets, as of Mar 2025, the value is 201.00 Cr.. The value appears strong and on an upward trend. It has increased from 167.00 Cr. (Mar 2024) to 201.00 Cr., marking an increase of 34.00 Cr..
- For CWIP, as of Mar 2025, the value is 5.00 Cr.. The value appears strong and on an upward trend. It has increased from 3.00 Cr. (Mar 2024) to 5.00 Cr., marking an increase of 2.00 Cr..
- For Investments, as of Mar 2025, the value is 0.00 Cr.. The value remains steady. There is no change compared to the previous period (Mar 2024) which recorded 0.00 Cr..
- For Other Assets, as of Mar 2025, the value is 208.00 Cr.. The value appears strong and on an upward trend. It has increased from 173.00 Cr. (Mar 2024) to 208.00 Cr., marking an increase of 35.00 Cr..
- For Total Assets, as of Mar 2025, the value is 414.00 Cr.. The value appears strong and on an upward trend. It has increased from 343.00 Cr. (Mar 2024) to 414.00 Cr., marking an increase of 71.00 Cr..
However, the Borrowings (179.00 Cr.) are higher than the Reserves (26.00 Cr.), which may signal higher financial risk.
Overall, while many items appear to show a positive trend, any significant downward movement or items where Borrowings exceed Reserves warrant further investigation.
Cash Flow - No data available for this post.
Free Cash Flow
| Month | Mar 2015n n 6m | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | Sep 2014n n 18m |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Free Cash Flow | 21.00 | -329.00 | -281.00 | -318.00 | -244.00 | -167.00 | -174.00 | -64.00 | -69.00 | -41.00 | -99.00 | 25.00 |
Free Cash Flow = Income Generated from Operational Activities - Borrowings - Capital Work in Progress (CWIP)
Consistent positive free cash flow is crucial for businesses as it indicates their ability to generate cash from their core operations. It provides financial flexibility, allowing companies to invest in growth opportunities, pay dividends to shareholders, reduce debt, and weather economic downturns more effectively.
Financial Efficiency Indicators
| Month | Sep 2014 | Mar 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Debtor Days | 57 | 144 | 65 | 71 | 29 | 41 | 50 | 32 | 45 | 52 | 56 | 70 |
| Inventory Days | 42 | 103 | 69 | 63 | 27 | 36 | 25 | 41 | 60 | 26 | 43 | 47 |
| Days Payable | 113 | 301 | 172 | 260 | 174 | 209 | 253 | 221 | 218 | 179 | 196 | 172 |
| Cash Conversion Cycle | -14 | -55 | -38 | -125 | -118 | -131 | -177 | -148 | -113 | -101 | -96 | -55 |
| Working Capital Days | -44 | -140 | -123 | -185 | -277 | -254 | -236 | -251 | -153 | -152 | -37 | 4 |
| ROCE % | 4% | 12% | 57% | -1% | 26% | 31% | 27% | 46% | 21% | 61% | 37% |
This stock is not held by any mutual fund.
Key Financial Ratios
| Month | Mar 25 | Mar 24 | Mar 23 | Mar 22 | Mar 21 |
|---|---|---|---|---|---|
| FaceValue | 10.00 | 10.00 | 10.00 | 10.00 | 10.00 |
| Basic EPS (Rs.) | 9.32 | 17.10 | -3.18 | 25.29 | -5.04 |
| Diluted EPS (Rs.) | 8.98 | 16.89 | -3.18 | 25.21 | -5.04 |
| Cash EPS (Rs.) | 13.38 | 21.07 | 0.60 | 28.45 | -1.14 |
| Book Value[Excl.RevalReserv]/Share (Rs.) | 18.09 | 8.53 | -10.03 | -7.17 | -62.46 |
| Book Value[Incl.RevalReserv]/Share (Rs.) | 18.09 | 8.53 | -10.03 | -7.17 | -62.46 |
| Revenue From Operations / Share (Rs.) | 182.94 | 175.79 | 152.77 | 156.49 | 156.91 |
| PBDIT / Share (Rs.) | 24.35 | 22.29 | 7.36 | 11.27 | 8.16 |
| PBIT / Share (Rs.) | 20.29 | 18.31 | 3.58 | 7.77 | 4.26 |
| PBT / Share (Rs.) | 9.02 | 17.20 | -3.15 | 24.84 | -4.96 |
| Net Profit / Share (Rs.) | 9.32 | 17.09 | -3.18 | 24.94 | -5.04 |
| NP After MI And SOA / Share (Rs.) | 9.32 | 17.09 | -3.18 | 24.94 | -5.04 |
| PBDIT Margin (%) | 13.31 | 12.67 | 4.82 | 7.20 | 5.20 |
| PBIT Margin (%) | 11.09 | 10.41 | 2.34 | 4.96 | 2.71 |
| PBT Margin (%) | 4.92 | 9.78 | -2.05 | 15.87 | -3.16 |
| Net Profit Margin (%) | 5.09 | 9.72 | -2.08 | 15.93 | -3.21 |
| NP After MI And SOA Margin (%) | 5.09 | 9.72 | -2.08 | 15.93 | -3.21 |
| Return on Networth / Equity (%) | 51.50 | 200.26 | 0.00 | -347.88 | 0.00 |
| Return on Capital Employeed (%) | 27.78 | 46.34 | -70.89 | -351.22 | -16.12 |
| Return On Assets (%) | 7.37 | 16.29 | -3.42 | 23.10 | -4.35 |
| Long Term Debt / Equity (X) | 2.70 | 2.93 | 0.00 | 0.00 | -0.46 |
| Total Debt / Equity (X) | 2.92 | 3.94 | -1.95 | -2.86 | -0.56 |
| Asset Turnover Ratio (%) | 1.58 | 1.78 | 1.52 | 1.60 | 1.39 |
| Current Ratio (X) | 1.11 | 0.74 | 0.38 | 0.48 | 0.28 |
| Quick Ratio (X) | 0.89 | 0.57 | 0.31 | 0.34 | 0.21 |
| Inventory Turnover Ratio (X) | 16.27 | 9.97 | 7.18 | 8.18 | 11.52 |
| Interest Coverage Ratio (X) | 2.16 | 2.50 | 1.13 | 1.79 | 0.88 |
| Interest Coverage Ratio (Post Tax) (X) | 1.83 | 2.04 | 0.54 | 1.25 | 0.45 |
| Enterprise Value (Cr.) | 929.36 | 581.65 | 182.26 | 319.37 | 284.21 |
| EV / Net Operating Revenue (X) | 1.55 | 1.01 | 0.36 | 0.62 | 0.72 |
| EV / EBITDA (X) | 11.64 | 7.97 | 7.57 | 8.67 | 13.92 |
| MarketCap / Net Operating Revenue (X) | 1.28 | 0.82 | 0.24 | 0.54 | 0.52 |
| Price / BV (X) | 12.97 | 17.09 | -3.72 | -11.86 | -1.33 |
| Price / Net Operating Revenue (X) | 1.28 | 0.82 | 0.24 | 0.54 | 0.52 |
| EarningsYield | 0.03 | 0.11 | -0.08 | 0.29 | -0.06 |
After reviewing the key financial ratios for Wanbury Ltd, here is a detailed analysis based on the latest available data and recent trends:
- For FaceValue, as of Mar 25, the value is 10.00. This value is within the healthy range. There is no change compared to the previous period (Mar 24) which recorded 10.00.
- For Basic EPS (Rs.), as of Mar 25, the value is 9.32. This value is within the healthy range. It has decreased from 17.10 (Mar 24) to 9.32, marking a decrease of 7.78.
- For Diluted EPS (Rs.), as of Mar 25, the value is 8.98. This value is within the healthy range. It has decreased from 16.89 (Mar 24) to 8.98, marking a decrease of 7.91.
- For Cash EPS (Rs.), as of Mar 25, the value is 13.38. This value is within the healthy range. It has decreased from 21.07 (Mar 24) to 13.38, marking a decrease of 7.69.
- For Book Value[Excl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.09. It has increased from 8.53 (Mar 24) to 18.09, marking an increase of 9.56.
- For Book Value[Incl.RevalReserv]/Share (Rs.), as of Mar 25, the value is 18.09. It has increased from 8.53 (Mar 24) to 18.09, marking an increase of 9.56.
- For Revenue From Operations / Share (Rs.), as of Mar 25, the value is 182.94. It has increased from 175.79 (Mar 24) to 182.94, marking an increase of 7.15.
- For PBDIT / Share (Rs.), as of Mar 25, the value is 24.35. This value is within the healthy range. It has increased from 22.29 (Mar 24) to 24.35, marking an increase of 2.06.
- For PBIT / Share (Rs.), as of Mar 25, the value is 20.29. This value is within the healthy range. It has increased from 18.31 (Mar 24) to 20.29, marking an increase of 1.98.
- For PBT / Share (Rs.), as of Mar 25, the value is 9.02. This value is within the healthy range. It has decreased from 17.20 (Mar 24) to 9.02, marking a decrease of 8.18.
- For Net Profit / Share (Rs.), as of Mar 25, the value is 9.32. This value is within the healthy range. It has decreased from 17.09 (Mar 24) to 9.32, marking a decrease of 7.77.
- For NP After MI And SOA / Share (Rs.), as of Mar 25, the value is 9.32. This value is within the healthy range. It has decreased from 17.09 (Mar 24) to 9.32, marking a decrease of 7.77.
- For PBDIT Margin (%), as of Mar 25, the value is 13.31. This value is within the healthy range. It has increased from 12.67 (Mar 24) to 13.31, marking an increase of 0.64.
- For PBIT Margin (%), as of Mar 25, the value is 11.09. This value is within the healthy range. It has increased from 10.41 (Mar 24) to 11.09, marking an increase of 0.68.
- For PBT Margin (%), as of Mar 25, the value is 4.92. This value is below the healthy minimum of 10. It has decreased from 9.78 (Mar 24) to 4.92, marking a decrease of 4.86.
- For Net Profit Margin (%), as of Mar 25, the value is 5.09. This value is within the healthy range. It has decreased from 9.72 (Mar 24) to 5.09, marking a decrease of 4.63.
- For NP After MI And SOA Margin (%), as of Mar 25, the value is 5.09. This value is below the healthy minimum of 8. It has decreased from 9.72 (Mar 24) to 5.09, marking a decrease of 4.63.
- For Return on Networth / Equity (%), as of Mar 25, the value is 51.50. This value is within the healthy range. It has decreased from 200.26 (Mar 24) to 51.50, marking a decrease of 148.76.
- For Return on Capital Employeed (%), as of Mar 25, the value is 27.78. This value is within the healthy range. It has decreased from 46.34 (Mar 24) to 27.78, marking a decrease of 18.56.
- For Return On Assets (%), as of Mar 25, the value is 7.37. This value is within the healthy range. It has decreased from 16.29 (Mar 24) to 7.37, marking a decrease of 8.92.
- For Long Term Debt / Equity (X), as of Mar 25, the value is 2.70. This value exceeds the healthy maximum of 1. It has decreased from 2.93 (Mar 24) to 2.70, marking a decrease of 0.23.
- For Total Debt / Equity (X), as of Mar 25, the value is 2.92. This value exceeds the healthy maximum of 1. It has decreased from 3.94 (Mar 24) to 2.92, marking a decrease of 1.02.
- For Asset Turnover Ratio (%), as of Mar 25, the value is 1.58. It has decreased from 1.78 (Mar 24) to 1.58, marking a decrease of 0.20.
- For Current Ratio (X), as of Mar 25, the value is 1.11. This value is below the healthy minimum of 1.5. It has increased from 0.74 (Mar 24) to 1.11, marking an increase of 0.37.
- For Quick Ratio (X), as of Mar 25, the value is 0.89. This value is below the healthy minimum of 1. It has increased from 0.57 (Mar 24) to 0.89, marking an increase of 0.32.
- For Inventory Turnover Ratio (X), as of Mar 25, the value is 16.27. This value exceeds the healthy maximum of 8. It has increased from 9.97 (Mar 24) to 16.27, marking an increase of 6.30.
- For Interest Coverage Ratio (X), as of Mar 25, the value is 2.16. This value is below the healthy minimum of 3. It has decreased from 2.50 (Mar 24) to 2.16, marking a decrease of 0.34.
- For Interest Coverage Ratio (Post Tax) (X), as of Mar 25, the value is 1.83. This value is below the healthy minimum of 3. It has decreased from 2.04 (Mar 24) to 1.83, marking a decrease of 0.21.
- For Enterprise Value (Cr.), as of Mar 25, the value is 929.36. It has increased from 581.65 (Mar 24) to 929.36, marking an increase of 347.71.
- For EV / Net Operating Revenue (X), as of Mar 25, the value is 1.55. This value is within the healthy range. It has increased from 1.01 (Mar 24) to 1.55, marking an increase of 0.54.
- For EV / EBITDA (X), as of Mar 25, the value is 11.64. This value is within the healthy range. It has increased from 7.97 (Mar 24) to 11.64, marking an increase of 3.67.
- For MarketCap / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.82 (Mar 24) to 1.28, marking an increase of 0.46.
- For Price / BV (X), as of Mar 25, the value is 12.97. This value exceeds the healthy maximum of 3. It has decreased from 17.09 (Mar 24) to 12.97, marking a decrease of 4.12.
- For Price / Net Operating Revenue (X), as of Mar 25, the value is 1.28. This value is within the healthy range. It has increased from 0.82 (Mar 24) to 1.28, marking an increase of 0.46.
- For EarningsYield, as of Mar 25, the value is 0.03. This value is below the healthy minimum of 5. It has decreased from 0.11 (Mar 24) to 0.03, marking a decrease of 0.08.
Overall, while many metrics show healthy performance, any figures highlighted in red or significant downward trends warrant further investigation.
Strength and Weakness
| Strength | Weakness |
|---|---|
|
|
Stock Analysis
- Considering all of the following key financial indicators, prospective investors are encouraged to conduct thorough research and seek professional guidance before considering any investment in Wanbury Ltd:
- Net Profit Margin: 5.09%
- Net Profit Margin: This metric indicates the percentage of profit a company makes from its total revenue. A higher net profit margin is generally desirable as it reflects better profitability.
- ROCE: 27.78% (Industry Average ROCE: 16.29%)
- ROCE (Return on Capital Employed): ROCE measures a company's profitability and the efficiency with which its capital is employed. A higher ROCE indicates efficient use of capital.
- ROE%: 51.5% (Industry Average ROE: 15.2%)
- ROE (Return on Equity): ROE measures a company's profitability relative to shareholders' equity. A higher ROE indicates efficient use of shareholders' funds.
- Interest Coverage Ratio (Post Tax): 1.83
- Interest Coverage Ratio: The interest coverage ratio measures a company's ability to cover its interest payments on outstanding debt. A ratio greater than 2 is generally considered healthy as it indicates the company can meet its interest obligations comfortably.
- Quick Ratio: 0.89
- Quick Ratio: The quick ratio assesses a company's ability to cover its short-term liabilities with its most liquid assets. A ratio higher than 1 suggests the company can meet its short-term obligations without relying heavily on inventory.
- Stock P/E: 18.9 (Industry average Stock P/E: 52.34)
- Stock P/E (Price-to-Earnings) Ratio: The P/E ratio compares a company's current share price to its earnings per share. A lower P/E ratio relative to industry peers or historical values may indicate that the stock is undervalued.
- Total Debt / Equity: 2.92
- Total Debt / Equity: This ratio measures a company's financial leverage by comparing its total debt to its total equity. A lower ratio indicates lower financial risk and greater financial stability.
Stock Rating: - Net Profit Margin: 5.09%
About the Company - Qualitative Analysis
| INDUSTRY | ADDRESS | CONTACT |
|---|---|---|
| Pharmaceuticals | BSEL Tech Park, B-Wing, 10th Floor, Sector 30-A, New Mumbai Maharashtra 400703 | cs@wanbury.com http://www.wanbury.com |
| Management | |
|---|---|
| Name | Position Held |
| Mr. K Chandran | Whole Time Director |
| Mr. Mohan Kumar Rayana | Whole Time Director |
| Ms. Anupama Vaidya | Ind. Non-Executive Woman Director |
| Mr. Mridul Sumanlal Mehta | Ind. Non-Executive Director |
| Mr. P V Sankar Dass | Ind. Non-Executive Director |
| Mr. Manojkumar K Gursahani | Ind. Non-Executive Director |
FAQ
What is the intrinsic value of Wanbury Ltd?
Wanbury Ltd's intrinsic value (as of 10 December 2025) is 213.55 which is 7.95% lower the current market price of 232.00, indicating overvalued. Calculated using the PE ratio method, this valuation considers the company's 814 Cr. market cap, FY2025-2026 high/low of 330/154, reserves of ₹26 Cr, and liabilities of 414 Cr.
What is the Market Cap of Wanbury Ltd?
The Market Cap of Wanbury Ltd is 814 Cr..
What is the current Stock Price of Wanbury Ltd as on 10 December 2025?
The current stock price of Wanbury Ltd as on 10 December 2025 is 232.
What is the High / Low of Wanbury Ltd stocks in FY 2025-2026?
In FY 2025-2026, the High / Low of Wanbury Ltd stocks is 330/154.
What is the Stock P/E of Wanbury Ltd?
The Stock P/E of Wanbury Ltd is 18.9.
What is the Book Value of Wanbury Ltd?
The Book Value of Wanbury Ltd is 18.1.
What is the Dividend Yield of Wanbury Ltd?
The Dividend Yield of Wanbury Ltd is 0.00 %.
What is the ROCE of Wanbury Ltd?
The ROCE of Wanbury Ltd is 36.7 %.
What is the ROE of Wanbury Ltd?
The ROE of Wanbury Ltd is 76.5 %.
What is the Face Value of Wanbury Ltd?
The Face Value of Wanbury Ltd is 10.0.